Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Dermatologic 1

Conditions

Melanoma 9Neoplasm Metastasis 3Urinary Bladder Neoplasms 1Skin Neoplasms 1Sarcoma, Synovial 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Fallopian Tube Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Cyclophosphamide 16pembrolizumab 14Radiosurgery 7Nivolumab 5Celecoxib 5poly ICLC 4Radiation 4Injections 4Radiotherapy 3Melphalan 3Ipilimumab 3Filgrastim 3Etoposide 3Docetaxel 3Cryosurgery 3Blood Specimen Collection 3Biopsy 3130-nm albumin-bound paclitaxel 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2fludarabine 2durvalumab 2cemiplimab 2atezolizumab 2aldesleukin 2Transurethral Resection of Prostate 2Therapeutics 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Decitabine × Dermatologic × Clear all
NCT02839694 2018-07-05

Adjuvant Oral Decitabine and Tetrahydrouridine With or Without Celecoxib in People Undergoing Pulmonary Metastasectomy

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡